Validation of the European Cross-Cultural Neuropsychological Test Battery (CNTB) for the assessment of mild cognitive impairment due to Alzheimer's disease and Parkinson's disease.
Alzheimer's disease
Parkinson's disease
cognitive assessment
cross-cultural neuropsychology
mild cognitive impairment
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
12
2022
accepted:
10
04
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
The Cross-Cultural Neuropsychological Test Battery (CNTB) is a novel test battery specifically designed to reduce the impact of multiculturality in cognitive assessment. We aimed to validate the CNTB in Spaniards in patients with Alzheimer's disease (AD), including patients at mild cognitive impairment (MCI) and mild dementia stages, and Parkinson's disease with MCI (PD-MCI). Thirty patients with AD-MCI, 30 with AD-dementia (AD-D), and 30 with PD-MCI were recruited. Each clinical group was compared against a healthy control group (HC) with no differences in sex, age, or years of education. Intergroup comparisons, ROC analysis, and cut-off scores were calculated. AD-MCI scored lower than HC in those subtests associated with episodic memory and verbal fluency. AD-D also showed lower scores in executive functions and visuospatial tests. Effect sizes for all the subtests were large. PD-MCI showed lower performance than HC in memory and executive functions, particularly on error scores, with large effect sizes. Comparing AD-MCI and PD-MCI, AD-MCI had lower memory scores, while PD-MCI showed the worst performance in executive functions. CNTB showed appropriate convergent validity with standardized neuropsychological tests measuring the same cognitive domains. We obtained similar cut-off scores to previous studies performed in other populations. The CNTB showed appropriate diagnostic properties in AD and PD, including those stages with mild cognitive impairment. This supports the utility of the CNTB for the early detection of cognitive impairment in AD and PD.
Sections du résumé
Background
UNASSIGNED
The Cross-Cultural Neuropsychological Test Battery (CNTB) is a novel test battery specifically designed to reduce the impact of multiculturality in cognitive assessment.
Objective
UNASSIGNED
We aimed to validate the CNTB in Spaniards in patients with Alzheimer's disease (AD), including patients at mild cognitive impairment (MCI) and mild dementia stages, and Parkinson's disease with MCI (PD-MCI).
Methods
UNASSIGNED
Thirty patients with AD-MCI, 30 with AD-dementia (AD-D), and 30 with PD-MCI were recruited. Each clinical group was compared against a healthy control group (HC) with no differences in sex, age, or years of education. Intergroup comparisons, ROC analysis, and cut-off scores were calculated.
Results
UNASSIGNED
AD-MCI scored lower than HC in those subtests associated with episodic memory and verbal fluency. AD-D also showed lower scores in executive functions and visuospatial tests. Effect sizes for all the subtests were large. PD-MCI showed lower performance than HC in memory and executive functions, particularly on error scores, with large effect sizes. Comparing AD-MCI and PD-MCI, AD-MCI had lower memory scores, while PD-MCI showed the worst performance in executive functions. CNTB showed appropriate convergent validity with standardized neuropsychological tests measuring the same cognitive domains. We obtained similar cut-off scores to previous studies performed in other populations.
Conclusions
UNASSIGNED
The CNTB showed appropriate diagnostic properties in AD and PD, including those stages with mild cognitive impairment. This supports the utility of the CNTB for the early detection of cognitive impairment in AD and PD.
Identifiants
pubmed: 37213535
doi: 10.3389/fnagi.2023.1134111
pmc: PMC10196233
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1134111Informations de copyright
Copyright © 2023 Delgado-Álvarez, Nielsen, Delgado-Alonso, Valles-Salgado, López-Carbonero, García-Ramos, Gil-Moreno, Díez-Cirarda, Matías-Guiu and Matias-Guiu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arch Clin Neuropsychol. 2021 Jul 19;36(5):815-830
pubmed: 33043958
Neurology. 2005 Oct 25;65(8):1239-45
pubmed: 16247051
Eur J Neurol. 2023 Mar;30(3):578-586
pubmed: 36380695
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Neurotherapeutics. 2022 Jan;19(1):26-54
pubmed: 35347644
Neuropsychologia. 2009 Oct;47(12):2464-9
pubmed: 19409401
J Clin Exp Neuropsychol. 2017 Mar;39(2):163-172
pubmed: 27501011
Front Aging Neurosci. 2022 Aug 23;14:963751
pubmed: 36081891
Neurologia. 2005 Oct;20(8):395-401
pubmed: 16217688
J Int Neuropsychol Soc. 2022 Oct;28(9):947-962
pubmed: 34569460
Neurology. 2003 Nov 11;61(9):1222-8
pubmed: 14610124
Arch Clin Neuropsychol. 2019 Jul 26;34(5):713-720
pubmed: 30272111
J Neuropsychol. 2013 Sep;7(2):193-224
pubmed: 24007368
Int Psychogeriatr. 2014 Apr;26(4):555-63
pubmed: 24423470
Int J Geriatr Psychiatry. 2019 Jul;34(7):982-989
pubmed: 30901493
Braz J Psychiatry. 2020;42(3):286-294
pubmed: 32130401
J Alzheimers Dis. 2015;49(3):617-31
pubmed: 26484931
Eur J Neurol. 2023 Apr;30(4):799-801
pubmed: 36445003
Arch Clin Neuropsychol. 2009 Jun;24(4):307-19
pubmed: 19549723
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Int J Geriatr Psychiatry. 2019 Nov;34(11):1724-1733
pubmed: 31389089
Int Psychogeriatr. 2004 Mar;16(1):13-31
pubmed: 15190994
J Clin Exp Neuropsychol. 2001 Jun;23(3):399-406
pubmed: 11419453
Clin Neuropsychol. 2022 Apr;36(3):546-557
pubmed: 34612169
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
J Alzheimers Dis. 2023;91(2):705-717
pubmed: 36502332
Arch Clin Neuropsychol. 2021 Apr 21;36(3):381-393
pubmed: 31942602
Int J Geriatr Psychiatry. 2019 Jan;34(1):144-152
pubmed: 30246268
Q J Exp Psychol (Hove). 2011 Mar;64(3):447-66
pubmed: 20839136
Ageing Res Rev. 2015 Sep;23(Pt B):183-92
pubmed: 26169474
J Psychiatr Res. 1982-1983;17(1):37-49
pubmed: 7183759
Int Psychogeriatr. 1998 Sep;10(3):261-70
pubmed: 9785147
Cold Spring Harb Perspect Med. 2012 Aug 01;2(8):
pubmed: 22908189
Clin Neuropsychol. 2018 Nov;32(8):1411-1430
pubmed: 29364089
Cortex. 2019 Apr;113:191-209
pubmed: 30660957
Mov Disord. 2012 Mar;27(3):349-56
pubmed: 22275317